RHHBY 39.23 Roche Holding AG
| Range: | 29.2-42.43 | Vol Avg: | 1649417 | Last Div: | 1.35 | Changes: | 0.35 |
| Beta: | 0.15 | Cap: | 251.52B | Currency: | USD | Exchange: | PNK |
| Sector: | Healthcare | IPO: | Wed Aug 20 2003 | Empoloyees: | 103605 | ||
| CUSIP: | 771195104 | CIK: | ISIN: | US7711951043 | Country: | CH | |
| CEO: | Dr. Thomas Schinecker | Website: | https://www.roche.com | ||||
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. The company was founded in 1896 and is headquartered in Basel, Switzerland.
Stock Details
Positive 0.67
Roche obtains CE certification for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOY
Basel, 10 October 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the VENTA...
globenewswire.com·Thu Oct 10 2024
Positive 0.21
Roche Has Over Five Weight-Loss Companion Medicines, CEO Says
Roche has more than five medicines that it could combine with weight-loss drugs, Chief Exe...
youtube.com·Tue Oct 01 2024
Neutral 0.00
Roche targets more than $3 billion in annual obesity sales
Roche said on Monday that three early-stage obesity and diabetes drug candidates from its ...
reuters.com·Mon Sep 30 2024
Neutral -0.05
Roche: The Devil Is In The Details - Obesity Data Presentation Disappoints
Shares of Roche Holding AG pulled back this month after disappointing tolerability data wa...
seekingalpha.com·Tue Sep 24 2024
Neutral 0.01
WHO endorses dual-stain cytology (CINtec PLUS) testing in its cervical cancer prevention guidelines, advancing patient care and underlining Roche's role in pioneering cervical cancer solutions
Basel, 23 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Wor...
globenewswire.com·Mon Sep 23 2024
Positive 0.12
TG Therapeutics: A Look At New Briumvi Data And Ocrevus Zunovo Approval
Shares of TG Therapeutics made new 52-week highs this week, helped in part by new Briumvi ...
seekingalpha.com·Sun Sep 22 2024
Negative -0.40
Roche Antiviral Drug Reduces Transmission in Late-stage Study
Results from a late-stage study on RHHBY's Xofluza show that the drug reduces the transmis...
zacks.com·Fri Sep 20 2024
Neutral 0.08
"Everyone Should Applaud" Powell for 50bps: Cullen Roche
Cullen Roche says the Fed is "thinking in a proactive sense" after announcing a 50BPS rate...
youtube.com·Wed Sep 18 2024
Positive 0.53
RHHBY or ABBV: Which Is the Better Value Stock Right Now?
Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Roche Ho...
zacks.com·Tue Sep 17 2024
Negative -0.52
Why Roche Holdings Stock Withered on Wednesday
The storied European pharmaceutical is forging ahead in its efforts to develop a weight lo...
fool.com·Wed Sep 11 2024
Neutral -0.06
Roche: Why I'm Not Concerned About Slight Sell-Off On Weight Loss Drug Safety Data
Roche stock has risen 22% since May due to promising GLP-1 agonist drug candidates, despit...
seekingalpha.com·Wed Sep 11 2024
Positive 0.30
Stratipath and Roche Join Forces to Help Expand Access to AI-Powered Precision Diagnostics
Stratipath, a global leader in artificial intelligence (AI)-based precision diagnostic sol...
globenewswire.com·Mon Sep 09 2024
Negative -0.22
Roche's fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with relapsing multiple sclerosis
Basel, 04 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present new 48-week dat...
globenewswire.com·Wed Sep 04 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow